Pulmatrix - press releases http://ir.pulmatrix.com/ Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSEā„¢ Formulation of Itraconazole http://ir.pulmatrix.com/2018-01-22-Pulmatrix-Announces-Acceptance-of-a-Clinical-Trial-Application-in-Europe-for-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic Mon, 22 Jan 2018 10:25:00 -0500 http://ir.pulmatrix.com/2018-01-22-Pulmatrix-Announces-Acceptance-of-a-Clinical-Trial-Application-in-Europe-for-Pulmazole-an-Inhaled-Dry-Powder-iSPERSE-TM-Formulation-of-Itraconazole Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials http://ir.pulmatrix.com/2017-11-09-Pulmatrix-Provides-Q3-2017-Highlights-and-Q3-2017-Updated-Financials Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of Pulmazole Thu, 09 Nov 2017 16:30:00 -0500 http://ir.pulmatrix.com/2017-11-09-Pulmatrix-Provides-Q3-2017-Highlights-and-Q3-2017-Updated-Financials Pulmatrix Presents at the North American Cystic Fibrosis Conference http://ir.pulmatrix.com/2017-10-31-Pulmatrix-Presents-at-the-North-American-Cystic-Fibrosis-Conference Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstream Tue, 31 Oct 2017 11:00:00 -0400 http://ir.pulmatrix.com/2017-10-31-Pulmatrix-Presents-at-the-North-American-Cystic-Fibrosis-Conference Pulmatrix Appoints Dr. James Roach as Chief Medical Officer http://ir.pulmatrix.com/2017-10-30-Pulmatrix-Appoints-Dr-James-Roach-as-Chief-Medical-Officer Dr. Roach will help Pulmatrix accelerate the development of its innovative inhaled drugs Mon, 30 Oct 2017 09:45:00 -0400 http://ir.pulmatrix.com/2017-10-30-Pulmatrix-Appoints-Dr-James-Roach-as-Chief-Medical-Officer Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA http://ir.pulmatrix.com/2017-10-03-Pulmatrix-Antifungal-Drug-Candidate-Receives-a-Second-Qualified-Infectious-Disease-Product-QIDP-Designation-from-the-FDA The FDA designation provides five years of market exclusivity for Pulmatrix's inhaled product for treating fungal infections in the lungs of patients with allergic bronchopulmonary aspergillosis Tue, 03 Oct 2017 09:45:00 -0400 http://ir.pulmatrix.com/2017-10-03-Pulmatrix-Antifungal-Drug-Candidate-Receives-a-Second-Qualified-Infectious-Disease-Product-QIDP-Designation-from-the-FDA